Altimmune (ALT) logo

Altimmune (ALT) stock

Pre-market
$1.67
+1.80%

Liver medicines, worth $313MGLP-1 and obesity drugs

Close $1.65 +2.17%

Why ALT fell on Nov 12

Down 17% on Nov 12 while the S&P 500 fell 0.4%.

  • Its Nov 12 results: net loss widened to $31.6M, from $19.0M a year before; research and development expenses were $27.0M, from $15.0M. It fell 17% on Nov 12.

Sources: Price history, Nov 12, 2026; Company release, Nov 12, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time ALT moves

Free account, no card. An optional alert when ALT moves or its score changes.Pro, 7 days free with a card. An optional alert when ALT moves or its score changes.

Or see it live, free until tomorrow morning. No account.
1 more reason, free with an account →2 more reasons why ALT fell on Nov 12, from its filings, with how the business stands, the timeline, and its peers, for Pro members.
Quality Score
-1
Poor
In its industry
#152of 270
Checks firing
2of 14
Trending down
From 52-week high
-74.5%
under its best in a year

ALT's Quality Score rose 4 points on Fri, Nov 13, to -1. Jerome Benedict Durso (President and CEO) bought $50K on Nov 13, filed Nov 13, and 2 more filings.

Follow ALT's trial news. Pro members can get an alert when Altimmune files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ALT files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2027“…is complete in the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027”Trial data · SEC filing · Nov 12
Cash$480M, about 18 quarters (4.5 years) at the last year's spendingOn Sep 30

Key facts on ALT

Key facts on ALT
Holding it back129.6% more shares than a year ago from Massive's market data
Latest filing8-K, Nov 12 Reported its quarterly results
1 more reason behind ALT's -1, free with an account →6 more reasons behind ALT's -1, for Pro members.

ALT in the news

Thu Nov 12Altimmune reported a loss of $0.15 a share SEC, 7:33 AM ET ALT closed −16.6% that day.

Big story

Get an alert on ALT's next big story →

Outlet counts from the GDELT Project. The move is what ALT did that session, not a claim about why.

1 more big story on ALT in the past 12 months, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$480M, about 18 quarters (4.5 years) at the last year's spendingOn Sep 30

ALT catalysts

Coming up

After its last 4 reports it closed -9.7% on average, higher 0 of 4 times.

5 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for ALT, and how long its cash lasts

Next step the company has named

2H 2027“Enrollment is complete in the RESTORE Phase 2 trial in ALD, with topline data expected in the second half of 2027”Trial data · SEC filing · Nov 12

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
PERFORMAPhase 3 · Recruiting · 1,800 people · main data estimated Dec 2028 · NCT07795164

1 more trial, 1 more milestone and 35 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 18 quarters

$480M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Nov 6, 2025)
  • At-the-market share sales program (S-3, filed Nov 6, 2025)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Director Wayne Pisano bought 10,000 shares on Nov 13. 10 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Jerome Durso’s 16 filings and quotes.

Get an alert when ALT files news on its trialsA free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

How ALT ranks in Biotech

ALT is #152 of 270 by Quality Score.

How ALT ranks in Biotech
RankStockQuality Score
152Altimmune (ALT) logoALTAltimmune-1

Cash and short-term investments: ALT $265M, GPCR $1.24B, MBX $482M.

More in Biotech

When does ALT report earnings, and what happens after?

Expected to report Thu Mar 4, before the open (in 108 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ALT reported on Nov 12, 2026

The quarter

A loss of $0.15 a share, from $0.21.

“The increase was driven primarily by an increase in compensation expenses and professional services”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

ALT's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value
$313M
today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ALT: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-1.9%-2.3%-16.6%
May 13Aug 12Nov 12
ReportedGapReaction5
days
Nov 12, 2026Before open-1.6%-16.6%not yet
Aug 12, 2026Before open+1.7%-2.3%-1.0%
May 13, 2026Before open-3.3%-1.9%-11.0%

ALT closed higher after 0 of its last 4 reports.

All 4 reports, and ALT's Quality Score going into each

ALT sales and profit by year

Sales and profit by year

Sales grew in three of the last five years, to $41K in 2025. It lost money in each of the seven years.

ALT has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ALT, and all 14 on every stock.Get in free →

ALT RSI on Nov 13: 26.5, below its 50-day and 200-day averages

Not scored

RSI 26.5, MACD below signal, below both averages. Not scored.

The deep dive on ALT

  • What it does and how it makes money3 findingsAn operating loss of $94.5M in fiscal 2025, on $41K of sales.Annual report, filed Mar 6, 2026"Pemvidutide is protected by a robust patent portfolio covering its composition, formulation, methods of use and treatment with patent expiration dates extending into the 2040s when the expected patent term extension is included." (10-K for fiscal 2025)SEC filing · Mar 6, 2026
  • Where it stands4 findingsFor Pro members4 findings on where ALT stands: its cash, debt, and share count, for Pro members
  • What changed in its filings8 findings"The complaint was based upon allegations that were similar to those alleged in a class action complaint previously filed against us in the Securities Class Action and alleged claims for violations of Section 14(a) of the Securities Exchange Act of 1934 …" (10-K for fiscal 2025)SEC filing · Mar 6, 2026A new heading in its "Risk Factors" this year: "We are currently in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by current regulatory activities and economic policies and events related thereto …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 6, 2026, against the one of Feb 27, 2025
  • Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades ALT, for Pro members
  • Against its closest peers2 peersCash and short-term investments: ALT $265M, GPCR $1.24B, MBX $482M.

14 more findings on ALT, each with its source, for Pro members.

ALT share count over time

130% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of ALT outstanding, as filed
Shares
outstanding
As
of
194.6MNov 6, 2026
194.5MAug 7, 2026
194.5MMay 8, 2026
130.1MFeb 27, 2026
Offerings, shelves, and splits of ALT, from its filings
From its
filings
Filed
Priced a sale of sharesApr 24, 2026
Priced a sale of sharesJan 28, 2026
Set up an at-the-market program for up to $200M of shares, about 64% of its market valueNov 6, 2025
Registered shares for a later sale (S-3)Nov 6, 2025

ALT insider trades

3 insiders bought $126K across 4 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyJerome Benedict Durso$50KPresident and CEOat $1.62 on Nov 13, filed Nov 13

All 4 insider filings on ALT from the last six months, for Pro members.

All ALT insider trades

ALT's officers and directors

Officers and directors with a Form 4 in the last 12 months.

3 more officers and directors file at ALT.

See insider trades by person

Which ETFs hold ALT?

In ETFs: ALT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Altimmune

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

57 employeesMorristown, NJaltimmune.com

What Altimmune says it competes with

“The biopharmaceutical industry is intensely competitive and is characterized by rapid technological progress.”

From its annual report, SEC filing · Mar 6, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ALT and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ALT's score around: 9 things
  • 10 more filings explained, a plain line each
  • 4 more things pulling ALT's score down
BreakawayNov 13Jerome Benedict Durso bought ALT$50K at $1.62, filed Nov 13

Alerts are optional.

See ALT's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: ALT's Quality Score is -1 (Poor), #152 of 270 in Biotech. Insiders bought $126K in the last 6 months (Form 4).

What does ALT's Quality Score say?

ALT scores -1 today, which Breakaway calls Poor. It is #152 of 270 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 17% on Nov 12 while the S&P 500 fell 0.4%. Cash lasts about 18 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ALT's Quality Score?

ALT scores -1 today, which Breakaway calls Poor (below zero). That is #152 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ALT's -1.

Are insiders buying ALT?

3 insiders bought $126K across 4 filings in the last 6 months. No open-⁠market sales on record. The newest is Jerome Benedict Durso, President and CEO, who bought $50K on Nov 13. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for Altimmune: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.